An Open Label Study With OHR/AVR118 in Advanced Cancer Patients with Anorexia-Cachexia.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs AVR 118 (Primary)
- Indications Anorexia; Cachexia
- Focus Therapeutic Use
- 26 Mar 2013 Results have been reported in an Ohr Pharmaceutical media release.
- 21 Mar 2013 Primary endpoint 'Bodyweight' (weight gain) has not been met according to an Ohr Pharmaceutical media release.
- 26 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.